Epithelioid
Significance of 18F-fluorodeoxyglucose PET/computed tomography in the initial staging of malignant peritoneal mesothelioma
Nuclear Medicine Communications 2025 May 6 [Link] Hui Zhang, Lifang Pang, Jun Hou, Beilei Li, Yiqiu Zhang Abstract Objective: This study was aimed at evaluating the significance of 18F-fluorodeoxyglucose PET/computed tomography (FDG PET/CT) in the staging and differentiation of malignant peritoneal mesothelioma (MPeM). Materials and methods: We retrospectively analyzed clinical and imaging data of 21…
Read MoreEfficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study
Medicina 2025 March 31 [Link] Ziya Kalkan, Senar Ebinc, Murat Arcagok, Ahmet Bilici, Ozcan Yildiz, Saadettin Kilickap, Deniz Can Guven, Ali Murat Tatli, Ahmet Taner Sumbul, Nil Molinas Mandel, Akin Ozturk, Murat Bardakci, Serdar Karakaya, Muhammet Ali Kaplan Abstract Background and Objectives: This study aimed to evaluate the effectiveness of immunotherapy compared to chemotherapy across…
Read MoreEfficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma
Lung Cancer 2025 May [Link] Ernest Nadal, Paloma Martín-Martorell, Jose Carlos Benítez, Maria Ángeles Sala, Susana Cedrés, Carlos Álvarez, Manuel Dómine, Elia Sais 8, Maria Saigí, Rafael López, Laia Vilà, Bartomeu Massutí, Rosario García-Campelo, Andres Mesas-Ruiz, Amelia Insa, Sílvia Plans-Marín, Sara Hijazo-Pechero, Cristina Muñoz-Pinedo, Jesús Brenes, Mariano Provencio Abstract Objectives: We aimed to evaluate the…
Read MoreAd-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Clinical Cancer Research 2025 April 10 [Link] Hee-Jin Jang, Meera Patel, Daniel Y Wang, Sung Wook Kang, Jong Min Choi, Claire Lee, Monica Vilchis, Ji Seon Shim, Sonali Mitra, Priyanka Ranchod, Allen Kuncheria, William Hudson, Peter Jindra, Veronica Lenge De Rosen, Maheshwari Ramineni, Ernest Ramsay Camp, Farrah Kheradmand, R Taylor Ripley, Shawn S Groth, Hyun-Sung…
Read MoreCD276 as a critical independent biomarker and immune checkpoint inhibitor target in epithelioid mesothelioma-TCGA study
Journal of Thoracic Disease 2025 January 24 [Link] Yuko Aoki, Ken Arimura, Kenzo Hiroshima, Yasuto Sato, Mitsuko Kondo, Etsuko Tagaya Abstract Background: CD276 is an immune checkpoint, and immune checkpoint inhibitors (ICIs) targeting CD276 have been tested against various cancers. However, the precise role of CD276 in mesothelioma subtypes is unknown. This study aimed to…
Read MoreDNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy
Journal of Experimental & Clinical Cancer Research 2025 February 18 [Link] Maria Fortunata Lofiego, Rossella Tufano, Emma Bello, Laura Solmonese, Francesco Marzani, Francesca Piazzini, Fabrizio Celesti, Francesca Pia Caruso, Teresa Maria Rosaria Noviello, Roberta Mortarini, Andrea Anichini, Michele Ceccarelli, Luana Calabrò, Michele Maio, Sandra Coral, Anna Maria Di Giacomo, Alessia Covre Abstract Background: Co-targeting of…
Read MorePrognostic Stratification of Epithelioid Pleural Mesothelioma Based on the Hippo-TEADs Network
Cancers 2025 January 30 [Link] Anello Marcello Poma, Rossella Bruno, Iacopo Petrini, Iosè Di Stefano, Alessandra Celi, Andrea Sbrana, Sabrina Cappelli, Antonio Chella, Franca Melfi, Marco Lucchi, Greta Alì Abstract Background. The Hippo pathway is the most frequently altered signaling in pleural mesothelioma (PM). Epithelioid PM (ePM) is associated with better outcome than non-epithelioid subtypes,…
Read MoreThe Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis
Medicina 2025 January 16 [Link] Nadiye Sever, Sedat Yıldırım, Ali Fuat Gurbuz, Delyadil Karakaş Kılıç, Esra Zeynelgil, Yunus Emre Altintaş, Berivan Deniz Çimik, Yeşim Ağyol, Ali Kaan Güren, Pınar Erel, Erkam Kocaaslan, Burak Paçacı, Mustafa Alperen Tunç, Abdussamet Çelebi, Nazım Can Demircan, Selver Işık, Rukiye Arıkan, Murat Araz, Serdar Karakaya, Murat Sarı, Osman Köstek, İbrahim…
Read MoreFollow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA
ESMO Open 2025 February [Link] L H Douma, M M Hofman, F Zwierenga, T M T Zondervan, A I G Buma, H Schouwink, D W Dumoulin, J A Burgers, I Smesseim, J G J V Aerts, C J de Gooijer Abstract Background: Diffuse pleural mesothelioma (dPM) is an aggressive malignancy, primarily treated with palliative systemic…
Read MoreAnalysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single-Center Retrospective Study
Oncology 2025 January 24 [Link] Tomoki Higashiyama, Kozo Kuribayashi, Hiroshi Doi, Aki Kubota, Taiichiro Otsuki, Yasuhiro Nakajima, Koji Mikami, Ryo Takahashi, Akifumi Nakamura, Daichi Fujimoto, Kazuhiro Kitajima, Toshiyuki Minami, Takashi Kijima Abstract Introduction: In August 2018, the Japanese PMDA approved nivolumab, an immune checkpoint inhibitor, for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (PM)…
Read More
Skip to content